Targeted intraoperative radiotherapy (Targit) yields very low recurrence rates when given as a boost

Jayant S. Vaidya, Michael Baum, Jeffrey S. Tobias, Samuele Massarut, Frederik Wenz, Olive Murphy, Basil Hilaris, Joan Houghton, Christobel Saunders, Tammy Corica, Mario Roncadin, Uta Kraus-Tiefenbacher, Frank Melchaert, Mohammed Keshtgar, Richard Sainsbury, Michael Douek, Elly Harrison, Alastair Thompson, David Joseph

    Research output: Contribution to journalArticlepeer-review

    79 Citations (Scopus)


    Purpose: Patients undergoing breast-conserving surgery were offered boost radiotherapy with targeted intraoperative radiotherapy (TARGIT) using the Intrabeam system to test the feasibility, safety, and efficacy of the new approach. Methods and Materials: We treated 302 cancers in 301 unselected patients. This was not a low-risk group. One-third of patients (98/301) were younger than 51 years of age. More than half of the tumors (172, 57%) were between 1 cm and 2 cm, and one-fifth (62, 21%) were >2 cm; 29% (86) had a Grade 3 tumor and, in 29% (87), axillary lymph nodes contained metastasis. After primary surgery, 20 Gy was delivered intraoperatively to the surface of the tumor bed, followed by external-beam radiotherapy (EBRT), but excluding the usual boost. Results: The treatment was well tolerated. The follow-up ranged from 3 to 80 months (164 and 90 patients completed 2 and 3 years follow-up, respectively). Four patients (1.3%) had local recurrence. The Kaplan-Meier estimate of local recurrence is 2.6% (SE = 1.7) at 5 years. This compares favorably with the 4.3% recurrence rate in boosted patients from the EORTC boost study, in which only 8.1% patients were node-positive, as opposed to 29% in our series. Conclusion: Targeted intraoperative radiotherapy combined with EBRT results in a low local recurrence rate. This could be attributed to both accurate targeting and timeliness of the treatment. These data support the need for a randomized trial to test whether the TARGIT boost is superior to conventional external boost, especially in high-risk women.
    Original languageEnglish
    Pages (from-to)1335-1338
    Number of pages4
    JournalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP)
    Issue number5
    Publication statusPublished - Dec 2006


    • Breast cancer
    • Breast conserving therapy/surgery
    • IORT
    • Targeted intraoperative radiotherapy (Targit)
    • Targit
    • Recurrence rate


    Dive into the research topics of 'Targeted intraoperative radiotherapy (Targit) yields very low recurrence rates when given as a boost'. Together they form a unique fingerprint.

    Cite this